1. Home
  2. LULU vs INCY Comparison

LULU vs INCY Comparison

Compare LULU & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo lululemon athletica inc.

LULU

lululemon athletica inc.

HOLD

Current Price

$173.43

Market Cap

19.9B

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$98.89

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LULU
INCY
Founded
1998
1991
Country
Canada
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.9B
17.0B
IPO Year
2007
1994

Fundamental Metrics

Financial Performance
Metric
LULU
INCY
Price
$173.43
$98.89
Analyst Decision
Hold
Buy
Analyst Count
25
21
Target Price
$212.97
$100.63
AVG Volume (30 Days)
1.9M
1.7M
Earning Date
03-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
20.00
4173.33
EPS
8.29
6.41
Revenue
$10,588,126,000.00
$3,394,635,000.00
Revenue This Year
$6.59
$11.02
Revenue Next Year
$4.40
$9.97
P/E Ratio
$21.05
$15.28
Revenue Growth
10.07
13.67
52 Week Low
$159.25
$53.56
52 Week High
$363.88
$112.29

Technical Indicators

Market Signals
Indicator
LULU
INCY
Relative Strength Index (RSI) 42.13 43.63
Support Level $160.62 $82.66
Resistance Level $184.31 $108.79
Average True Range (ATR) 6.32 2.89
MACD 0.21 -0.30
Stochastic Oscillator 21.33 28.49

Price Performance

Historical Comparison
LULU
INCY

About LULU lululemon athletica inc.

Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 780 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 40 franchised locations in the Middle East and Europe. The company was founded in 1998 and is based in Vancouver, Canada.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: